PMID- 24212937
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20131111
LR  - 20240109
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 3
IP  - 3
DP  - 2011 Jul 13
TI  - Two Domains of Vimentin Are Expressed on the Surface of Lymph Node, Bone and 
      Brain Metastatic Prostate Cancer Lines along with the Putative Stem Cell Marker 
      Proteins CD44 and CD133.
PG  - 2870-85
LID - 10.3390/cancers3032870 [doi]
AB  - Vimentin was originally identified as an intermediate filament protein present 
      only as an intracellular component in many cell types. However, this protein has 
      now been detected on the surface of a number of different cancer cell types in a 
      punctate distribution pattern. Increased vimentin expression has been indicated 
      as an important step in epithelial-mesenchymal transition (EMT) required for the 
      metastasis of prostate cancer. Here, using two vimentin-specific monoclonal 
      antibodies (SC5 and V9 directed against the coil one rod domain and the 
      C-terminus of the vimentin protein, respectively), we examined whether either of 
      these domains would be displayed on the surface of three commonly studied 
      prostate cancer cell lines isolated from different sites of metastases. Confocal 
      analysis of LNCaP, PC3 and DU145 prostate cancer cell lines (derived from lymph 
      node, bone or brain prostate metastases, respectively) demonstrated that both 
      domains of vimentin are present on the surface of these metastatic cancer cell 
      types. In addition, flow cytometric analysis revealed that vimentin expression 
      was readily detected along with CD44 expression but only a small subpopulation of 
      prostate cancer cells expressed vimentin and the putative stem cell marker CD133 
      along with CD44. Finally, Cowpea mosaic virus (CPMV) nanoparticles that target 
      vimentin could bind and internalize into tested prostate cancer cell lines. These 
      results demonstrate that at least two domains of vimentin are present on the 
      surface of metastatic prostate cancer cells and suggest that vimentin could 
      provide a useful target for nanoparticle- or antibody- cancer therapeutic agents 
      directed against highly invasive cancer and/or stem cells.
FAU - Steinmetz, Nicole F
AU  - Steinmetz NF
AD  - Case Western Reserve University, Department of Biomedical Engineering, 10900 
      Euclid Ave, Cleveland, OH 44106, USA. tbraciak@tpims.org.
FAU - Maurer, Jochen
AU  - Maurer J
FAU - Sheng, Huiming
AU  - Sheng H
FAU - Bensussan, Armand
AU  - Bensussan A
FAU - Maricic, Igor
AU  - Maricic I
FAU - Kumar, Vipin
AU  - Kumar V
FAU - Braciak, Todd A
AU  - Braciak TA
LA  - eng
GR  - R00 EB009105/EB/NIBIB NIH HHS/United States
GR  - R01 CA100660/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20110713
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC3759176
EDAT- 2011/01/01 00:00
MHDA- 2011/01/01 00:01
PMCR- 2011/07/13
CRDT- 2013/11/12 06:00
PHST- 2011/05/24 00:00 [received]
PHST- 2011/06/27 00:00 [revised]
PHST- 2011/07/06 00:00 [accepted]
PHST- 2013/11/12 06:00 [entrez]
PHST- 2011/01/01 00:00 [pubmed]
PHST- 2011/01/01 00:01 [medline]
PHST- 2011/07/13 00:00 [pmc-release]
AID - cancers3032870 [pii]
AID - cancers-03-02870 [pii]
AID - 10.3390/cancers3032870 [doi]
PST - epublish
SO  - Cancers (Basel). 2011 Jul 13;3(3):2870-85. doi: 10.3390/cancers3032870.